posted by user: Rachel || 3967 views || tracked by 3 users: [display]

Free Cell Press Webinar 2015 : Cancer Immunoediting: Implications for Cancer Immunotherapy

FacebookTwitterLinkedInGoogle

Link: http://view6.workcast.net/register?pak=1147739887088638
 
When Mar 12, 2015 - Mar 12, 2015
Where Online webinar
Submission Deadline TBD
Categories    cancer   immunotherapy   immunoediting
 

Call For Papers

While the immune system attempts to constrain tumor growth, tumor cells often escape this immune pressure, in a manner similar to tumor cell evasion of classic tumor suppression mechanisms. The dual host-protective and tumor-promoting actions of immunity are referred to as cancer immunoediting. Cancer immunoediting emphasizes that extrinsic immune pressure either can block tumor growth, development, and survival or can facilitate tumor outgrowth by shaping tumor immunogenicity and inhibiting host-protective antitumor responses. In this webinar, Nir Hacohen and Robert Schreiber discuss recent advances in our understanding of cancer immunoediting and the implications for cancer immunotherapy.

Related Resources

Optogenetics 2024   4th Optogenetic Technologies and Applications Conference
IITUPC 2024   Immunotherapy and Information Technology: Unleashing the Power of Convergence
FGRT SCPC 2024   Frontiers in Genetics Research Topic - Single Cell RNA Expression in Pancreatic Cancer
IITUPC 2024   Immunotherapy and Information Technology: Unleashing the Power of Convergence
EAICI 2024   Explainable AI for Cancer Imaging
IEEE-JBHI (SI) 2024   Special Issue on Revolutionizing Healthcare Informatics with Generative AI: Innovations and Implications
Call for Chapters - CRC Press 2024   Internet of Things: Challenges and Advances
IEEE-EMBS BHI 2024   IEEE-EMBS International Conference on Biomedical and Health Informatics
Call for Chapters - Wiley-IEEE Press 2024   Internet of Things A to Z: Technologies and Applications - Second Edition
DLGM 2024   Call For Book Chapters 2024: Deep Learning in Genome Mapping, CRC Press (Taylor & Francis Group)